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Background: Care coordination is imperative to successful patient outcomes. However, 
community pharmacists are commonly excluded from health information exchange 
during care coordination. One of the ways pharmacists deliver care, through medication 
therapy management (MTM), could be optimized if pharmacists engaged in care 
coordination through review of unedited patient medical records in preparation for a 
section of the MTM, the comprehensive medication review (CMR). 
 
Methods: This was a non-blinded randomized controlled trial undertaken within the 
Medication Safety Research network of Indiana, also known as RxSafeNet. RxSafeNet is a 
community pharmacy practice based research network. Pharmacists were randomized 
to deliver CMR’s to adult patients under usual care, or with a care coordination 
intervention. The intervention consisted of soliciting the patient-identified primary care 
provider-held medical records of the last six months. Medication related problems 
(MRPs) identified and omissions in preventative care identified were recorded for each 
CMR delivered. Additionally, pharmacists were surveyed over their thoughts and 





Results: Thirty seven patients were seen for CMR appointments. Intervention 
pharmacists identified more MRP’s than usual care pharmacists. The intervention,  
while controlling for predictor variables included in a multiple linear regression model, 
had an adjusted R2= 0.511; p=0.05. Intervention pharmacists identified more omissions 
in preventative care (adjusted R2= 0.136; p=0.027). 
Intervention pharmacists were more likely to agree they were confident they identified 
all of the patient’s MRPs (47.1% vs. 15.8%), but neither group was more likely than the 
other to believe they had resolved all MRPs (41.2% vs. 42.1%). Lastly, intervention 
pharmacists agreed 100% of the time that the patient’s health history helped them 
complete a better CMR as compared with only 69% of usual care pharmacists. 
 
Conclusion: Community pharmacists identify more MRPs and omissions in preventative 
care when they engage in care coordination by reviewing the patient’s PCP’s unedited 














One of the many ways community pharmacists deliver patient care is through 
Medication Therapy Management, otherwise known as “MTM.” MTM can be thought of 
as an umbrella term referring to a group of services pharmacists offer, such as 
medication therapy reviews and pharmacotherapy consults, which are utilized to 
identify, prevent, and resolve medication-related problems (MRPs)(American  
Pharmacist Association 2013). Effective MTM is imperative, as an estimated 1.5 million 
preventable medication-related adverse effects at an expense of $177 billion occur each 
year in the United states(Ernst and Grizzle 2001). However, evidence of MTM’s 
effectiveness has varied extensively (Fox, Ried et al. 2009, Pindolia, Stebelsky et al. 
2009, Welch, Delate et al. 2009, Winston and Lin 2009, Moczygemba, Barner et al. 2011, 
Ward and Xu 2011) and this variation can be attributed to a lack of service 
standardization and optimization. One of the Core Elements of MTM, the 
Comprehensive Medication Review (CMR), is a process that could be targeted for such 
optimization. CMRs consist of pharmacists’ review and reconciliation of a patient’s 
prescription and non-prescription medications to promote overall health and identify 





coordination (i.e. sharing of available patient health information) among health 
professionals (Hume, Kirwin et al. 2012). Thus the ability of community pharmacists to 
detect and resolve health-related problems, either medication related or preventive- 
care related, may be diminished. 
Evidence from numerous studies show that when pharmacists engage in care 
coordination, positive impacts such as enhanced medication-related problem detection 
and resolution are realized. This has resulted in many hospitals including pharmacists in 
admission, discharge and follow-up programs (Bolas, Brookes et al. 2004, Schnipper, 
Kirwin et al. 2006, Kramer, Hopkins et al. 2007, Kwan, Fernandes et al. 2007, Varkey, 
Cunningham et al. 2007, Gorgas Torner, Gamundi Planas et al. 2008, Midlov, Holmdahl 
et al. 2008, Bergkvist, Midlov et al. 2009, Walker, Bernstein et al. 2009, Eggink, 
Lenderink et al. 2010, Hellstrom, Bondesson et al. 2011, Midlov, Bahrani et al. 2012). 
However, similar care coordination efforts in the community setting are limited. It is 
unknown how out-patient pharmacists in the community utilize medication records in 





The United States Agency for Healthcare Research and Quality (AHRQ), as a part of the 
Department of Health and Human Services, defines care coordination as “the deliberate 
organization of patient care activities between two or more participants (including the 





different aspects of care”(McDonald, Sundaram et al. 2007). The Centers for Medicare 
and Medicaid Services (CMS) and the Institute of Medicine (IOM) have identified poor 
care coordination as a major health problem within the United States, due to its 
staggering risk to patient safety: sixty-six percent of all medication-related errors are 
attributed to poor care coordination(Santell 2009). Consequently, standardized and 
effective mechanisms are needed to facilitate effective health information exchange  
and thus the 2010 Affordable Care Act (ACA) highlights care coordination measures.  As 
a part of the ACA’s meaningful use of care coordination, the Office of the National 
Coordinator for Health Information Technology (ONC) has promoted state electronic 
Health Information Exchanges (HIE’s) which allow healthcare workers and patients alike 
to securely access medical information electronically. Specifically, as part of the ONC’s 
vision, pharmacies will participate in Health Information Exchange, but pharmacists are 
not eligible to receive any reimbursement for offsetting the cost of electronic health 
record (EHR) implementation under CMS’s Electronic Health Records Incentive 
Program(US Centers for Medicare and Medicaid 2015). The list of eligible professions 
under the EHR incentive program is quite lengthy, including dentists, nurse  
practitioners, nurse midwifes, doctors of medicine, osteopathy, surgery, podiatry, 
optometry and chiropractors. Additionally, under CMS Meaningful Use stipulations, the 
above mentioned professionals are required to provide summary care records during all 





pharmacists. Furthermore, Indiana’s HIE, the Indiana Health Information Exchange, does 
not engage community pharmacists. 
Pharmacists are even further discouraged to engage in care coordination as they are not 
recognized providers under the Social Security Act and therefore ineligible to bill 
Medicare Transitional Care Management Services’ CPT codes directly (Snow, Beck et al. 
2009). Therefore, medication reconciliation during care coordination is billable by most 
healthcare providers except pharmacists, who are the medication experts. Despite being 
cited as the most trusted and accessible healthcare professional, and despite the fact 
that community pharmacies filled over 3.7 billion prescriptions in 2011, community 
pharmacists remain underutilized to contribute positively to care coordination. 
Regardless of the barriers faced by pharmacists to provide patient care, opportunities 
exist for community pharmacists to identify and address health-related problems in the 
form of CMRs. Health- related problems can be medication-related in nature, but not 
necessarily so. Pharmacists also ameliorate health-related problems related to 
preventive-health, as community pharmacists regularly identify and correct missing 
preventive-care recommendations by delivering immunizations. 
Indeed, one of preventive healthcare’s recent and greatest success has been increased 
access to immunizations through community pharmacist-delivered vaccinations. 
American community pharmacists began vaccinating in the early 1990’s, and mass 





Control and Prevention (CDC) in 1996 (Terrie 2010). Today all 50 state legislations 
recognize community pharmacists’ ability to vaccinate, and literature from national data 
shows that by allowing pharmacists to provide vaccinations, the rate of influenza 
immunization has increased (Steyer, Ragucci et al. 2004). Any time a pharmacist 
interacts with a patient is an opportunity to screen for missing vaccinations, especially 
during the one-on-one CMR. As such, community pharmacists may intervene on other 
preventive care measures, as prevention is reliant on availability and access to 
healthcare. Sufficient availability and access however is in stark contrast to the current 
state of American healthcare- with its challenges of quality, cost and access, amplified by 
a national shortage of primary care providers. Indeed, the Commissioned Corps of       
the US Public Health Service has identified pharmacists’ contribution to increasing 
preventive care access by serving as extensions of public health infrastructure,  
increasing services’ quality, and partnering with other healthcare providers (Scott 
Giberson 2011). Because of this, it is reasonable to believe that pharmacies might serve 
as care delivery or referral sites for other preventive measures above-and-beyond 
vaccinations. 
In summary, despite pharmacists’ ability to detect MRPs and omissions in preventive 
care, community pharmacists are underutilized in their ability to contribute to care 
coordination teams. Furthermore, American laws discourage community pharmacists 
from engaging in care coordination. Due to the paucity of literature related to- and 





specifically analyzing community pharmacists’ efficacy in detecting health-related 
problems when engaging in care coordination, in the form of health information 






It is postulated that when community pharmacists engage in care coordination and thus 
review patients’ medical histories in preparation for a CMR, that immediate outcomes 
(i.e. detection of health-related problems) will improve, but this has yet to be tested. 
Touchette et al. studied the effect of pharmacists’ review of medical record during a 
CMR on adverse drug event rates, but pharmacists in this study were not in community 
settings and information provided to the pharmacists were interpretations of the 
medical record (consisting of a two-page standardized synopsis) rather than the 
unedited and complete records (Touchette, Masica et al. 2012). Another study 
undertaken by Warholak-Juarez et al. within the Indian Health Services explored 
pharmacists’ use of medical history. These researchers demonstrated that pharmacists 
provide better patient care (i.e. identify and resolve more problems) when given more 
complete patient medical histories on which to base their decisions. However, 
Warholak-Juarez et al.’s patient cases were also edited and standardized (Warholak- 
Juarez, Rupp et al. 2000). Understanding community pharmacists’ interpretation and 
utilization of unedited and complete electronic medical records is warranted. While 





evaluation of standardized medical histories, this model does not reflect current 
community pharmacy practice as medical histories HIE information exchange is limited. 
Additionally, in the rare chance that health information is shared with community 
pharmacists, the information is unedited and non-standardized. Consequently, research 
is needed to discern community pharmacists’ effectiveness in discovering health-related 








Specifically, our research team sought to determine if community pharmacists identify 
more health-related problems including MRPs, and omissions of preventive-care. We 
seek to answer: “Do pharmacists who review medical records in preparation for a 
comprehensive medication review (CMR) identify more MRPs than pharmacists who do 
not?,” and characterize the types of MRPs identified between pharmacists who review 
medical records and those who do not. Additionally, we aimed to answer: “Do 
pharmacists who review medical records in preparation for a comprehensive medication 
review (CMR) identify more omissions in recommended preventive care than 
pharmacists who do not?,” and characterize types of preventive care omissions found 
between community pharmacists who review medical records and those who do not. 
We also aimed to characterize the types of health records received from primary care 





problems. Lastly, we aimed to ascertain community pharmacists’ perceived usefulness 
of available health history, be-it attained from unedited medical records or solely from 
the patient. 
The research described below may provide evidence towards recognizing community 
pharmacists as an integral part of the healthcare team, and allow community 
pharmacists to engage in patient-centered collaborative care with prescribers and other 
healthcare workers. Long-term, we expect this research will (1) build on existing 
evidence demonstrating that pharmacists should be recognized as health care providers 
under the Social Security Act and as eligible providers for incentives under the CMS 















This study was designed as a prospective randomized controlled trial to take place 
within the Medication Safety Research Network of Indiana (Rx-SafeNet). Rx-SafeNet is a 
state-wide community pharmacy practice based research network (PBRN), registered as 
an affiliate member with the U.S. Agency for Healthcare Research and Quality (AHRQ) 
PBRN Resource Network. The Network, comprised of 181 community pharmacies across 
Indiana, serves to facilitate collaboration among researchers and clinicians to research 
medication safety and advance community pharmacy. The mission of Rx-SafeNet is to 
“improve medication safety and advance community pharmacy practice in Indiana 






Planning for the study began in in July 2013 by defining the three outcomes measures. 
The primary outcome was total number of MRPs identified per patient as defined by the 
taxonomy described in Cipolle, Strand & Morley’s Pharmaceutical Care Process: The 
Clinician’s Guide (Cipolle RJ 2004.). A secondary outcome was total number of 





Preventative Services Task Force A & B Recommendations (See Appendix)(United States 
Preventative Services Task Force 2013). The third and final outcome was pharmacist 
reported perceptions and beliefs towards utilizing patients’ health history, despite how 
it was obtained (i.e. verbally for usual care pharmacists, verbally and from medical 
records for intervention pharmacists) for each CMR delivered. 
 
 
Study Design Timeline 
 
In July 2013, following the Network’s policy for study selection, the project idea was 
proposed to the Rx-SafeNet Executive Committee, and approved the same month. Rx- 
SafeNet site coordinators voted to pursue the study after voting via an email survey in 
August, 2013. A preliminary protocol was developed and subsequently reviewed by the 
Rx-SafeNet project review team (PRT) in October 2013. 
The PRT is a committee of 3 College of Pharmacy faculty who review draft study 
protocols submitted to Rx-SafeNet for feedback on protocol improvement. In  
September of 2013, the Purdue University Statistical Consulting service issued guidance 
on the protocol’s data analysis methods, and the final protocol was approved by the PRT 
in January, 2014. Final approval by the Purdue University Institutional Review Board 







It was decided that the intervention would not be tested in a pre-existing service, 
because although limited MTM services occur throughout Indiana and in Rx-SafeNet 
locations, use of these consultations for comparison would have been challenging due to 
a small number of patients receiving MTM and the wide variety in medication-related 
problem taxonomies routinely employed. Therefore, study pharmacists were trained to 
provide comprehensive medication reviews (CMRs) with and without care coordination, 
as applicable, to create an appropriate comparison group. 
The intervention consisted of care coordination in preparation for the CMR by means of 
a HIPAA release soliciting the last six months of medical records to the patient-identified 
primary care provider by fax. The release itself not only requested records originated by 
the primary care provider, but all records obtained by the PCP through care  
coordination from other entities. This HIPAA release, explicitly requested release of 
protected health information for research purposes. This included the last six months 
of: (1) the patient’s problems list; (2) laboratory test results; (3) allergies; (4) the 
patient’s medication list; (5) immunization, surgical, device and family history and (6) 
the previous six months of known encounters, including any specialist, walk-in, care 
coordination, hospital or other healthcare provider encounter. The HIPAA waiver 
stipulated if the latest diabetic, osteo-, respiratory, lipid, endocrine, hepatic, 
hematological, and/or drug concentration(s) lab results fell outside of the previous six 





The six above criteria were chosen to be requested as they reflect information outlined 
at the time by CMS’s Stage1: Eligible Professional Menu Objectives Core Measure 8. This 
Core Measure stipulated that any eligible provider who transitioned a patient to another 
care setting should provide a care summary to that setting. Currently,              
community pharmacists and pharmacies are not eligible providers under this CMS 
measure and neither transmit nor receive care summary sheets during transitions of 
care. 
Thus, both groups of pharmacists received health information, but in two different 
approaches. Intervention pharmacists received the patient-health history verbally from 
the patient and from the PCP-provided medical record, whereas usual care pharmacists 





Pharmacist Recruitment as Non-Key Personnel 
 
Community pharmacists were eligible to assist with the study as non-key personnel if 
they certified that they did not routinely request medical records from patients’ 
providers. It was believed that pharmacists who regularly requested patients’ medical 
records would have a learning effect on reviewing such history. Recruitment of 
community pharmacists within Rx-SafeNet began in March, 2014. Twenty-three 
pharmacy site coordinators, representing the 168 pharmacy locations within Rx-SafeNet 





from either the Rx-SafeNet Network Manager or Dr. Gernant. It was at the discretion of 
the pharmacy site coordinator to share the study’s information to allow participation 
with the then existing recruitment pool of 312 network pharmacists. An estimated 125 
pharmacists were informed of the study, as some site coordinators declined 
involvement. A total of 10 pharmacists within Rx-SafeNet representing 9 pharmacies, 
expressed interest in participating and agreed to undergo research training. However 
due to time constraints, only six completed training and three were lost to attrition (See 
Figure 1). Five replacement pharmacists were engaged, four of which were within 
RxSafeNet. Due to high attrition and low engagement, pharmacist enlistment was 
expanded outside the Network, and one non-member of Rx-SafeNet participated in the 
study. 
Pharmacists were chosen to be the point of randomization as randomization at the 
patient level could have potentially contaminated the intervention by learning effects 
experienced by the pharmacists. Originally, the study was designed to stratify 
pharmacists based on their experience level, defined as year in practice, involvement in 
any post-graduate training, and number of CMRs completed in the previous year. 
However, this method of stratification was not used due to the high level of attrition; 
rather a simple binomial random number generator was used to randomize pharmacists 








Figure 1. Study Pharmacist Recruitment and Attrition 
Estimated 125 
Pharmacists 
Informed of Study 
10 Pharmacists 
Agreed to Training 
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One-on-one pharmacist training sessions began after IRB approval in April, 2014. The 
seventh and final pharmacist recruited for the study was trained in August, 2014. 
Pharmacists were required to complete Human Subjects Research training online 
through University of Miami’s Collaborative Institutional Training Initiative (CITI) 
modules and undergo one time face-to-face training with Dr. Gernant. Details of these 
training sessions are discussed below. 
 
 
CITI Module Training 
 
All study pharmacists were required to complete Human Subjects Research Training for 
Non-Key Personnel through the Collaborative Institutional Training Initiative. 
Pharmacists were categorized as non-key personnel as they recruited and consented 
patients, but did not contribute in a substantive, measurable way to the study’s 
scientific development. Pharmacists were required to complete an integrity assurance 
statement certifying that they agreed to the ethical conditions required by CITI training; 
namely, pharmacists certified that they would complete CITI training without assistance, 
with one active account and without engagement in activities that would improve results 
for themselves or others. Required training for non-key personnel included the   
following nine modules: (1) A review of the Belmont Report and CITI course  
introduction, (2) Students in Research, (3) History and Ethical Principles of Human 





Privacy and Confidentiality, (7) Records-Based Research, (8) Populations in Research 
Requiring Additional Considerations and/or Protections, and (9) Conflicts of Interests in 
Research Involving Human Subjects. Completion of all eight modules were required, 
with an average score of at least 80% on post-module quizzes. Upon completion, a 
certificate was generated with the date completed and total score; Dr. Gernant 






At the commencement of training, pharmacists signed an understanding certifying that 
they met all study criteria needed to act as non-key personnel (see Pharmacist 
Recruitment as Non-Key Personnel). Pharmacists underwent one-on-one study training 
with Dr. Gernant and were given a training manual that included a protocol regarding 
CMR delivery. The following sections explain the process of training study pharmacists 




Pharmacist Training: Protocol Training 
 
Protocol training for study pharmacists included a step-by-step introduction to 
completing CITI module training, defining patient eligibility, classifying results and data 





how to obtain HIPAA releases and medical records. Intervention pharmacists were 
instructed to fax the signed HIPAA release form to the patient-identified primary care 
provider at least 10 days before their scheduled CMR. If the pharmacists did not receive 
patient records within 48 hours of faxing the HIPAA release, the pharmacist was 
instructed to call the prescriber’s office. If the pharmacist received nothing from the 
patient’s prescriber’s office within 72 hours before the scheduled CMR, the pharmacist 
was instructed to call the prescriber’s office a second time. Intervention patients whose 
prescriber’s office did not send records to the pharmacy were excluded from 
participation. All pharmacists were at liberty to schedule/reschedule appointments 
based on the convenience for the pharmacist and the patient. Pharmacists were 
instructed to call the patient 24 hours before their appointment as a reminder. 
 
 
Pharmacist Training: Informed Consent 
 
Informed consent training was critical as pharmacists participating in the study had no 
previous experience consenting patients. In addition to the informed consent training 
provided in CITI module training, Dr. Gernant role-played consent with each trainee. 
Furthermore, pharmacists were given a list of informed consent policies adapted by the 
guidance given by the Purdue University IRB, and reviewed this with Dr. Gernant. 
Examples of these policies include delivering informed consent in clear, understandable 
every-day language, and allowing the patient to ask questions throughout the process. 





pharmacist may have had a pre-existing relationship with the patient. It was stressed to 
study pharmacists that even after reviewing the consent form, many patients may not 
yet understand basic information about the risks and benefits of study participation. 
Pharmacists were trained to have patients state the study’s purpose and to specifically 
explain what was being asked of them in their own words. All pharmacists reported 
understanding that patients were ineligible for participation if the patient could not 




Pharmacist Training: Recruitment Logs 
 
 
Study pharmacists were required to keep recruitment logs, itemizing potential 
participants who had been approached and consented for study participation. The 
recruitment log served as a record of the number of patients approached for IRB 
reporting purposes and CMR scheduling. The log also served as a reminder to 
intervention pharmacists to obtain medical records. The recruitment logs were gathered 
by Dr. Gernant at the end of the data collection period. 
 
 
Completing a CMR 
 
Regardless of the level of experience, all pharmacists underwent Medication Therapy 
Review (MTR) training delineating differences between a Comprehensive Medication 





introduced to the concept of “pharmaceutical care”(Hepler and Strand 1990), in which 
pharmacists intervene to prevent, identify and resolve medication problems. 
Pharmacists were asked to identify and resolve problems by considering the following 
four questions as reflected in the Pharmaceutical Care Process: (1) is the medication 
indicated?; (2) Is the medication effective?; (3) Is the medication safe?; and (4) Is the 
patient able to adhere to the medication regimen? 
 
 
Completing a CMR: Extracting Information 
 
Dr. Gernant refreshed pharmacists on the basics of extracting health information by 
reviewing the SOAP note process, and the difference between subjective and objective 
information. “SOAP” is an acronym for “subjective, objective, assessment, and plan,” 
and is a method employed by health care providers to document patient encounters. 
This training was included to highlight the difference between study data (identified 
MRP’s and preventive care omissions) and clinical decisions made at the discretion of 
the pharmacist. A blank SOAP template was provided to study pharmacists to facilitate 




Completing a CMR: MRPs 
 
 
Dr. Gernant introduced study pharmacists to categorizing and identifying MRPs by 





Process: The Clinician’s Guide (Cipolle RJ 2004.)(see Table 1). In an effort not to limit 
pharmacists, examples of MRPs that did not clearly fall into a single classification were 
included in a case review. For example, a medication may need adjustment based on 
serum concentrations which had not been monitored. If an identified problem was not 
easily classified, pharmacists were instructed to choose the classification most closely 
related. Additionally, pharmacists were instructed to classify a problem only once, even 





Table 1.  MRPs Classification 
 
Category Medication-Related Problem 
No valid medical indication for the drug therapy at this time 
Multiple drug therapies are being used for a condition that requires 



































Medical condition is more appropriately treated with nondrug 
therapy 
Drug therapy is being taken to treat an avoidable adverse reaction 
associated with another medication 
Drug abuse, alcohol use, or smoking is causing the medical problem 
Medical condition requires the initiation of drug therapy 
Preventative drug therapy is required to reduce the risk of 
developing a new condition 
Medical condition requires additional drug therapy to attain 
synergistic or additive effects 
Drug product is not the most effective product for the indication 
being treated 
Medical condition is refractory to the drug product 
Dosage form of the drug product is inappropriate 
Drug is not effective for the medical problem 
Dose is too low to produce the desired response 
Dosage interval is too infrequent to produce the desired response 
Drug interaction reduces the amount of active drug available 
Duration of drug therapy is too short to produce the desired 
response 
Drug product causes an undesirable reaction that is not dose-related 
Safer drug product is required due to risk factors 
Drug interaction causes an undesirable reaction that is not dose- 
related 
Dosage regimen was administered or changed too rapidly 
Drug product causes an allergic reaction 
Drug product is contraindicated due to risk factors. 
Dose is too high 
Dosing frequency is too short 
Duration of drug therapy is too long 
Drug interaction occurs in a toxic reaction to the drug product 
Dose of the drug was administered too rapidly 
Patient did not understand instructions 
Patient prefers not to take medication 
Patient forgets to take medication 
Drug product is too expensive for the patient 
Patient cannot swallow or self-administer appropriately 








Completing a CMR: Preventative Care Omissions; the 2013 U.S. Preventative Services 
Task Force A & B Recommendations 
All pharmacists who were involved in the study attained their PharmD, and thus had 
received basic training covering preventive care within the standard Doctor of Pharmacy 
curricula. Examples of preventive care measures pharmacists usually receive training on 
include colonoscopies, breast and prostate cancer screens, smoking cessation and 
aspirin use for myocardial infarction prophylaxis. However, despite their training, 
community pharmacists do not routinely engage in preventive care services aside from 
vaccination delivery. Therefore, a platform was required to justify the preventive care 
measures in which pharmacists could focus their care. Upon literature and policy  
review, it was decided that the United States Preventative Task Force (USPSTF) A & B 
Recommendations were the most complete and up-to-date list of preventive measures 
that applied to the study’s target population. 
Prior to training, all study pharmacists had never encountered the USPSTF’s 
recommendations. During the section of this training, pharmacists were introduced to 
the history and reasons for the USPSTF’s recommendations’ development. Each 
recommendation related to adults and seniors were reviewed, however 
recommendations’ related to pregnancy and children were excluded, as these patients 
were not included in this study for IRB purposes. “Women of child bearing age” was 





Partner Violence” screening described screening for any physical, sexual, or 
psychological harm caused by a current/former partner/spouse occurring in either 
heterosexual or same-sex couples. As of 2013, this screening recommendation applied 




Completing a CMR: Preventative Measures; The CDC’s Advisory Committee on 
Immunization Practices 
A refresher on the CDC’s Adult Immunization schedule was included in study training 
about preventive care (US Centers for Disease Control and Prevention, 2013). 
Pharmacists reviewed information regarding the number of doses, intervals between 





Pharmacist Training: Data Recording 
 
The data collection form was developed as an online survey with the Qualtrics® platform 
and all pharmacists were instructed to transmit data over the pharmacy’s secure  
wireless network, or the secure network identified by both the pharmacist and the 
Purdue researchers. The Qualtrics® survey collected data related to patient 





perceptions about using the health history obtained, either be it verbal from the 
patient, from the medical records or both. Pharmacists had the option of completing 
the Qualtrics® survey via iPad, or their work desktop computer. 
During training to assure pharmacists understood data entry, Dr. Gernant gave 
pharmacists a simulated patient case that included a mock patient’s medical history 
(including social/family history), recent labs, medication list, vitals and allergies. The 
pharmacist was instructed to review the case, and identify any MRPs and possible 
preventive care omissions. Once the case was reviewed, the pharmacist completed a 
mock data collection form for practice. If there was any discrepancy in the manner in 
which the pharmacists completed the mock data form, Dr. Gernant discussed this with 
the pharmacist until an agreement was reached on data transmission. 
At the end of each Qualtrics® data collection form was a short survey measuring 
pharmacists’ beliefs and attitudes towards utilizing health history in their CMR. Both 
intervention and usual care pharmacists were instructed to complete this section, as 
both groups did have some health history available to them- namely usual care 
pharmacists attained health history verbally from the patient, whereas intervention 
pharmacists attained health history from the patient, as well as from unedited medical 
records. However, only intervention pharmacists were asked to complete questions 
regarding their opinions on usability of certain parts of the medical records, as usual 
care pharmacists did not have access to these. 
25 
 
Patient Eligibility and Recruitment 
 
After study power at 80% with an alpha of 0.05was calculated to detect a minimum 
difference of two MRP’s between groups, it was decided 90 patients would be sought  
for recruitment, 45 within each group. Patients were recruited face-to-face either by the 
study pharmacist or by Dr. Gernant when they visited their community pharmacy to drop 
off or pick up a prescription. Pharmacists were given a checklist inclusion and     
exclusion criteria and were instructed to ask each potential participant every question 
before the invitation for study participation. 
Patient inclusion criteria was modeled after Medicare Part D MTM criteria, but expanded 
to all adults of all ages to increase the pool of patients for study. Thus                     
patients were included if they agreed to undergo an CMR with the pharmacist and met 
the following criteria: (1) At least four chronic prescription medications scheduled for a 
chronic medical condition filled at the study pharmacy; (2)  At least one of the following 
chronic disease states: hypertension, heart failure, diabetes, dyslipidemia, respiratory 
disease (such as asthma, chronic obstructive pulmonary disease, or chronic lung 
disorders), bone disease-arthritis (such as osteoporosis, osteoarthritis, or rheumatoid 
arthritis), or mental health conditions (such as depression, schizophrenia, bipolar 
disorder); (3) had an office visit with their Primary Care Provider within the last six 





excluded if they met any one of the following criteria: (1) were under 18 years of age; 
 
(2) was a prisoner, or incarcerated; (3) was a university student; (4) was pregnant; (5) 
was unable to give informed consent or; (6) had received a CMR from a pharmacist 
within the previous six months. Patients were excluded from study participation if they 
had received a CMR within the previous six months from a pharmacist, as it was thought 




Data Collection Related to Pharmacists 
 
Pharmacist demographics were collected at the time of study training and included 
number of years of active practiced, the number of CMRs completed within the previous 
year, and if the pharmacist had any post-graduate training/certification (Residency, 
Fellowship, or Board Certification). This data was collected to account for differences 






Upon study completion, pharmacists were invited to participate in an exit interview with 
Dr. Gernant. These interviews served as a quality improvement opportunity for study 
pharmacists to provide feedback regarding study logistics, and to discuss barriers and 





private exit interviews using an interview guide either telephonically or face-to-face at 
the pharmacists’ pharmacy. Interviews were not audio-recorded, notes and quotations 
of pharmacists’ responses were typed during the interview. These transcriptions were 






Pharmacists were compensated at a rate of $75 per CMR, regardless of their assignment 
to intervention or usual care groups, which is comparable to market reimbursement for 
MTM (Mirixa 2013). If pharmacists in the intervention group did not receive any records 
from the PCP despite following procedures, the pharmacy was allowed to invoice the 
investigative team $10. It was left to the pharmacists’ discretion to continue and 
complete the CMR, however the patient’s data were not included as a part of this study. 
Patients were compensated for their time with a $25 Visa gift-card. This compensation 
was approved by the Purdue University IRB, with the stipulation that a log of patient’s 
identities be recorded to track payment receipt. Patient’s compensation was sent via 














The research team consulted with Purdue’s statistical consulting service to develop a 
data analysis plan. All analyses for this study were performed using IBM Statistical 




Pharmacist and Patient Demographics Analysis 
 
Mann-Whitney U tests were used to detect differences in demographic variables (years 
practicing and number of CMRs delivered) between pharmacists groups, as pharmacists 
were acting as non-key personnel, and differences in experience would expectedly 
affect study outcomes. Differences among patient groups’ comorbidities and race were 
tested with Pearson chi-square tests or fisher’s exact test for cells that had an expected 
count of less than five. Age, number of comorbidities, and total number of medications 





Primary Outcome Analysis: MRPs Identification 
 
The primary outcome, total number of MRPs discovered, was analyzed using an 





distributed. Significance of the intervention was then tested with a multivariate linear 
regression model fit to relate study variables to the number of MRPs discovered. To do 
this, bivariate statistics were computed for each predictor variable; bivariates on 
categorical data were computed using either a Mann-Whitney or a kruskal-wallis test. 
Correlation between continuous data and the number of MRPs identified was computed 
with spearman’s rho. Variables with a p-value less than 0.2 were included in a 
multivariate linear regression model. 
The assumptions of linear regression were verified- linearity was checked with a line of 
best fit in a plot of residual vs. predicted values. A correlation matrix and variance 
inflation factors/tolerance values were identified to assure that multi co-linearity was 
not present, and a durbin-watson test was run to ensure that the residuals were 
independent. A p-p-plot was used to verify Homoscedasticity. 
The study team also sought to identify if there were differences between groups in the 
types of MRP’s identified. Therefore, a Mann-Whitney U test was again used to test for 
differences in the numbers of each of the four types of MRP’s (i.e., indication, efficacy, 




Secondary Outcome Analysis: Preventative-Care Omission Identification 
The total number of applicable USPSTF recommendations was calculated for each 
patient based on the pharmacist-entered data. Determination of each patient’s number 





reported comorbidities. If based on the available data it was uncertain to researchers if 
a USPSTF recommendation applied to a particular patient, then that recommendation 
was counted, as it could not be ruled out. This was done because the USPSTF 
recommendations’ purpose is to both screen for and identify possible preventive care 
omissions. For example, the USPSTF has several preventive care screening 
recommendations for persons who are at risk for sexually-transmitted infections. Those 
at risk may be sex industry workers, injection drug users, or those who have multiple 
partners; this information was not specifically gathered by the Qualtrics® data collection 
form, and therefore could not be ruled out. Healthcare workers utilizing the USPSTF 
recommendations need assure patients’ eligibility for each recommendation. 
Differences in the number of preventive-care omissions identified between groups were 
tested for significance using a t-test. A linear regression model was fit to isolate the 
effect of the intervention by the same methods outlined in section 3.1. 
The number of preventive care omissions identified for each recommendation was 




Secondary Outcome Analysis: Pharmacists’ Perceptions of Utilizing Health History 
Pharmacists’ perceptions towards medical history’s usefulness was characterized with 
descriptive statistics. Perceptions towards records received and utilized were 
















Despite replacement for attrition, only four of the seven study pharmacists completed 
any CMRs. Due to the high attrition, the low recruitment and the overall slow rate of 
CMR completion, researchers decided to include all pharmacists who underwent 
training, whether they completed a CMR or not, in exit interviews to identify barriers 
and facilitators to study workflow and participation. Two usual care study pharmacists 
completed 19 CMRs and three intervention pharmacists completed 17 CMRs between 
June, 2014 and February 2015. Of the four pharmacists who completed CMRs, one 
usual care pharmacist and one intervention pharmacist had post graduate training. All 
pharmacists were female and opted to transmit data via their work desktop computer. 
There was no statistical differences in number of CMRs provided in the last year, nor 
years practicing between groups. Other demographics related to study pharmacists’ 










Thirty-six patients were recruited and seen for CMRs during the intervention period; 17 
were seen by intervention pharmacists and 19 by usual care pharmacists. The majority 
of patients were female (86%) and Caucasian (75%). Patients in the intervention group 
were more complex than patients in the usual care group, with significantly more 
comorbidities and number of medications, and were more likely to be diagnosed with 
asthma, dyslipidemia, obesity and osteoporosis (see Table 3 below). Additionally, there 
were significant differences in patients’ race between groups; all intervention patients 
were Caucasian and usual care patients were either African American or Caucasian. 
There were no differences in the average total number of preventive care omissions 






Table 2.  Study Pharmacists’ Experience 
 




Mean Min Max Std  Mean Min Max Std p 
 
 Number of 
CMRs  
Provided in Last 
Year 
6.7 0 20 11.5 
 





5.0 2 7 2.6 
 







Table 3.  Patient Demographics and Morbidities 
 Intervention (n=17) Usual Care (n=19) p-value 
Demographics Median (IQR) Median (IQR)  
Age┼ 45 (39-52) 43 (33-49) 0.20 
Total # of Medications┼ 15 (11-16.5) 8 (6-11) <0.01* 
Total #of Comorbidities┼ 5 (4.5-7) 3 (3-4) <0.01* 
 
n (%) n (%) 
 
Female‡ 15 (88.2) 16 (84.2) 0.56 
African American‡ 0 (0) 7 (36.8) 0.01* 
Asian‡ 0 (0) 2 (10.5) 0.49 
White‡ 17 (100) 10 (52.6) <0.01* 
Comorbidities‡ n (%) n (%) 
 
Asthma 4 (23.5) 0 (0) 0.04* 
Chronic 
Pain/Fibromyalgia 
5 (29.4) 4 (21.1) 0.71 
Congestive Heart Failure 0 (0) 2 (10.5) 0.49 
COPD 2 (11.8) 2 (10.5) 1.00 
Depression 9 (52.9) 8 (42.1) 0.52 
Diabetes 8 (47.1) 7 (36.8) 0.54 
Dyslipidemia 14 (82.4) 9 (47.4) 0.01* 
GERD 6 (35.3) 3 (15.8) 0.25 
Hypertension 15 (29.4) 13 (68.4) 0.24 
Obesity 4 (23.5) 0 (0) 0.04* 
Osteoporosis 4 (23.5) 0 (0) 0.04* 
RA 3 (17.6) 1 (5.3) 0.33 
‡ Pearson chi-square or fisher’s exact test 




Outcome: MRPs Identified 
 
Intervention pharmacists identified significantly more MRPs per patient than usual care 
pharmacists (11 [IQR: 7-14.5] vs. 6 [IQR: 4-9] problems per patient, p=0.02). Intervention 





effectiveness) than usual care pharmacists; that is, intervention pharmacists identified 
more: (1) Medical conditions requiring the initiation of drug therapy; (2) Medication 
dosages too low to produce the desired response; (3) Medication interactions resulting 
in undesirable reactions that were not dose-related; (4) Patients who did not 
understand medications’ instructions and (5) Preventative therapies required to reduce 
the risk comorbidity development. 
Variables identified with bivariate analysis to predict the number of MRPs discovered 
included total number of medications, total number of comorbidities, asthma, and 
depression. All variables entered into the multiple linear regression model to predict 
number of MRPs were significant with the exception of depression, and the overall 
model was significant (adjusted R2= 0.511; p<0.01). The intervention, while controlling 
for all variables included in the predictor model, was, B= 0.351, CI: 0.005-13.96; p=0.05. 
Furthermore, the model improved with the addition of intervention variable into the 
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Medication Related Problem Type Intervention 
Usual Care 















Table 4.  MRPs Discovered┼ 














23 0 (0-1.5)  15 0 (0-2) 153.5 0.80 
Needs 
Additional Drug 
52 3 (2-4)  20 0 (0-2) 264.5 <0.01 
Indication Total 75 0 (0-3)  35 0 (0-2) 239.5 0.01 
 
 
        
Needs Different 
Drug Product 
26 0 (0-3)  20 0 (0-2) 162.5 0.98 
Dosage Too 
Low 
27 2 (0-2.5)  12 0 (0-2) 218.5 0.07 
Effectiveness 
Total 




        
Adverse Drug 
Reaction Total 
40 2 (0-5)  9 0 (0-1) 221.0 0.06 
Dosage Too 
High 
19 0 (0-0)  6 0 (0-0) 169.0 0.827 
Safety Total 59 2 (0-6)  15 0 (0-2) 204.0 0.18 
 
 




65 4 (2-6)  46 0 (0-4) 218.5 0.07 




Outcome: Preventative Care Omissions Identified 
 
Intervention pharmacists identified, on average, 3.4 preventive care omissions per 
patient, compared to an average of 2.5 omissions per patients seen by usual care 
pharmacists (a median of 3 [IQR 3-4] vs. a median of 3 [IQR:1-3] omissions identified per 
patient; p=0.04). There were statistical differences in types of preventive-care omissions 
discovered between groups; intervention pharmacists were more likely than usual care 
pharmacists to identify a need for depression screening/counseling, healthy diet 
counseling, and missing immunizations. In contrast, usual care pharmacists identified 
significantly more patients who needed blood pressure screenings than intervention 
pharmacists. Other notable preventive care omissions identified by pharmacists, but  
not included in the United States Preventative Service Task Force A & B 
recommendations, pertained to healthy amounts of physical activity and accessing  
other healthcare resources (e.g., social workers, financial counselors, keeping all 
scheduled doctor appointments). Neither intervention nor usual care pharmacists ever 
identified preventive care omissions related to breast cancer medications, folic acid 
supplementation, intimate partner violence, sexually transmitted diseases, nor skin 
cancer behavior. See Table 5 below for a full representation of preventive care 
omissions identified by pharmacists. 
Only two variables were identified with bivariate analysis to predict the number of 





multiple linear regression model to predict number of preventive care omissions 
discovered, the model itself was significant (adjusted R2= 0.136; p=0.027). Hypertension 
was non-significant, but did increase the predicted model’s r-squared, so it was retained 
in the final model testing the effect of the intervention. The model improved with the 
addition of the intervention variable from R2= 0.136 to R2= 0.238, and the model 

























Alcohol Misuse 19 0 (0%) 17 1 (6%) 0.48 
Aspirin Use 4 2 (50%) 9 3 (33%) 0.65 














Breast Cancer 16 1 (6%) 15 2 (13%) 0.59 
Cervical Cancer 16 1 (6%) 15 0 (0%) 1.00 
Cholesterol 19 6 (32%) 17 3 (18%) 0.45 
Colorectal Cancer 2 2 (100%) 5 6 (100%) 0.11 
Depression 19 0 (0%) 17 4 (57%) 0.04 
Diabetes 19 6 (32%) 17 5 (29%) 1.00 
Falls Prevention 0 1 (-) 0 3 (-) -- 
Folic Acid 11 0 (0%) 7 0 (0%) -- 
Healthy Diet 19 4 (21%) 17 10 (59%) 0.04 
Intimate Partner 
Violence 
11 0 (0%) 7 0 (0%) -- 
Missing 
Immunization 
19 4 (21%) 17 10 (59%) 0.04 
Obesity 19 1 (6%) 17 4 (24%) 0.17 
Osteoporosis 16 2 (13%) 15 2 (13%) 1.00 
Skin Cancer 
Behavioral 
0 0 (0%) 0 0 (0%) -- 
















19 6 (32%) 17 1 (6%) 0.09 






Outcome: Records Received and Perceived Usefulness 
 
Only one intervention pharmacist was denied access to the patient’s medical record 
after multiple attempts, resulting in a 97% response rate from prescriber’s offices. 
Additionally, 94% of the time, intervention pharmacists had access to at least one 
medical record note. Intervention pharmacists were most likely to receive active 
medication lists, allergy lists, problem lists, office visit notes and blood pressure 
readings. Intervention pharmacists cited drug levels, active medication lists, 
discontinued medication lists, problem lists, order notes, glucose/A1C labs, drug 
concentration labs, lung function tests and lipid panels as the most useful pieces of 
information (i.e., useful in ≥50% of cases received). Additionally, pharmacists received, 
but never utilized the following medical records to discover MRPs: liver/kidney function; 
medication indication & start/stop dates; complete blood counts; thyroid stimulating 
hormone levels; walk in, care coordination & hospitalization notes; and family, surgical, 
device & social history. A graphical representation of perceived usefulness can be seen 




Pharmacists’ Perceptions to Utilizing Health History 
Intervention pharmacists were more likely to strongly agree or agree they were 
comfortable using the health history obtained to make patient specific 





pharmacists reported that patients’ health information was clearer and more 
understandable more often than usual care pharmacists (93.7% vs. 21.1%). 
Pharmacists who had access to patient medical records were more likely to agree that 
they were confident they identified all of the patient’s MRPs (47.1% vs. 15.8%). 
However, neither group was more likely than the other to believe they had actually 
resolved all the patient’s medication problems (41.2% vs. 42.1%). Lastly, intervention 
pharmacists agreed that the patient’s health history helped them complete a better 
CMR more often than usual care pharmacists (100% vs. 68.5%). 
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Walk-in Clinic Notes 
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Figure 5. Pharmacist’s Opinions of Utilizing Health History 
Having the patient’s medical records helped me 
















I was confident I identified all the medication   I was confident I identified created a plan to resolve 
related problems the patient had all the medication related problems the patient had 
I was comfortable using the health history to make 
patient specific recommendations 
The patient’s health history was clear and 
understandable 
































After pharmacists were interviewed, themes related to barriers and facilitators 
emerged; there were a number of limitations due to the low recruitment rate and few 
CMRs completed. A major limitation identified by all pharmacists was finding time to fit 
in study activities (especially recruitment) into normal workflow responsibilities. 
 
“Time was a huge issue. As a retail pharmacist, even with the 
overlap, you still have your own responsibilities.” 
 
 
Pharmacists also reported limitations related to decision support tools, and identified 
confidence issues (concurrent with their feelings they had not resolved all identified 
issues) in regards to resolving identified problems. 
“I looked up things I learned long ago but hadn’t used in practice. 
Interaction checks weren’t helpful. I would get a possible 
“serotonin syndrome,’ but I need more research on it. I didn’t 
know if I had to be worried about it.” 
 
 
Time constraints were an emergent theme, and some pharmacists opted to perform the 
CMR directly after recruiting the patient, however this was only possible for usual care 
pharmacists, as intervention pharmacists had to wait for medical records to be released 
from the PCP. Pharmacists who opted to schedule patients, either in the intervention or 
usual care groups, identified patient reluctance to attending CMR appointments. 
“You really have to sell it to the patients- it’s like I have to pull teeth to 
try and help you, and if [it] was your doctor asking, I think they’d be 





prescriber, and you don’t come, you don’t get your prescription….it’s 
something that they just don’t see that they need." 
 
 
Additionally, pharmacists felt that patients may not have responded well to scheduling 
CMRs as this was an unfamiliar relationship with the pharmacist. 
“People around here, MTM is new, and people aren’t interested 
in sitting one on one with a pharmacist. It’s just not a common 




“Patients just weren’t interested, but they just kept avoiding us. I 
thought I had one, but they would never come in. I don’t know 
why they weren’t interested- maybe it was because they had to 
schedule instead of doing it on the fly.” 
 
 
Several other barriers mentioned by pharmacists were related to workflow issues and 
having to complete multiple projects simultaneously. Pharmacists who had devoted 
time away from the filling process in a private location found completing CMRs easier 
than those who participated in the study between checking prescriptions. By study 
design, intervention pharmacists had much more time-requirements; some pharmacists 
reported having to review full stacks of patient records before the CMR. However, none 
of the intervention pharmacists, upon direct questioning, reported that the records 
were ever cumbersome to review. Barriers related to time revolved centrally around 





“I would have to stop and restart because I was getting 
interrupted. I would forget what they took last.” 
 
 
“We are trying to schedule at least one pharmacist as the 
MTM pharmacist per day. And they are away from dispensing 
in a room so it’s easier to contact people.” 
 
 
There were few mixed themes reported by pharmacists; specifically pharmacists 
identified other pharmacy team members as barriers or facilitators based on whether 
the colleague would do extra work while the pharmacist was away from prescription 
filling responsibilities. 
“I had great techs who could multitask while I was away. The 
techs would take the phone calls, type and adjust the pickup 
time. They were doing this on their own. Sometimes they would 
ask patients to come back tomorrow after dropping off.” 
 
 
“My manager was supportive; they would cover when I was 
talking to patients and then went to a private area.” 
 
 
Lastly, pharmacists felt positively about delivering CMRs. They voiced they were able to 
develop better relationships with patients, and appreciated being able to talk to 
patients whom they considered needed their services the most. 
 
 
“I really liked that I wasn’t restricted in who I could provide the 
service to. I could pick people that I felt actually needed the 
service. The people I chose were frequent fliers, so it was very 







“In the future, I’ll do more med review to build rapport with the 
patients. Not in a room, but over the counter. “The more the 
patients get to know me, the more questions they ask. The study 
patients, they really stop by now. Even when they don’t have any 
prescriptions. They come by to show me their grandkids, and just 
talk to me personally.” 
 
 
“I liked having the time to get to know the patients. I wouldn’t 















In this study, we hypothesized that community pharmacists would be more effective in 
detecting health-related problems if they had access to some of the patient’s health 
history mirrored to information requested in CMS’ Meaningful Use Stage 1, Core 
Measure 8: Transitions of Care Summaries. This core measure dictates that certain 
health history be transferred to a receiving healthcare entity; however only “eligible 
providers” are counted under this core measure, which exclude pharmacists. 
Additionally, only eligible providers can receive incentives through CMS’s Electronic 
Health Record Incentives Program which supports the adoption, implementation and 
improvement of EHR technology for providers who demonstrate meaningful use. We 
hypothesized community pharmacists could add benefit to HIE for two reasons: (1) 
pharmacies have the most up-to-date medication list and fill history; and (2) 
pharmacist-delivered patient care services (MTM), could be optimized when 
pharmacists engage in transitions of care (i.e.: reviewing health information generated 
by another healthcare entity). We confirmed that intervention pharmacists found 
significantly more MRPs than pharmacists who deliver CMRs under usual care. 
Additionally, intervention pharmacists found more MRPs in every single domain (i.e., 





differences were only statistically significant for MRPs related to indication. A very 
recent study conducted by van Lint, Sorge and Sorensen, had similar results(van Lint, 
Sorge et al. 2015); in this study pharmacy residents completed MTM’s without patient 
records, and then verified medication problems discovered with pre-existing health 
history. Over half of the MRP’s discovered in the van Lint study were related to 
indication. MRP’s related to indication may have been discovered most often because 
pharmacists are highly educated on indication, but very rarely receive indication 
information in usual practice. Nearly significant results related to adherence MRP’s may 
have been discovered more often by intervention pharmacists, as patients’ instructions 
may have been documented in the medical chart, but never transcribed to the 
prescription and subsequently cued the pharmacist to identify discrepancies between 
what the patient was instructed, and what the patient actually did. 
In addition to discovering more MRP’s, intervention pharmacists also identified more 
preventive care omissions than usual care pharmacists overall, however both groups  
had certain omissions identified more often than their comparator group. Intervention 
pharmacists were more likely to identify omissions related to depression, diet, and 
immunizations whereas usual care pharmacists were more likely to identify that the 
patient was missing preventive care related to blood pressure screenings. We suspect 
intervention pharmacists discovered more missing immunizations because community 
pharmacists are highly trained in adult immunizations, but rarely have access to the 




identify blood pressure preventive care omissions because hypertension is a condition 
regularly addressed in the community pharmacy setting; intervention pharmacists may 
have been more concerned with omissions discovered from the PCP-obtained health 
history, as this was not part of their usual practice. 
Neither intervention pharmacists nor usual care pharmacists identified any preventive 
care omissions related to sexually transmitted diseases nor domestic abuse. We 
presume community pharmacists may have felt uncomfortable asking about highly 
sensitive subjects and/or may have felt inadequately trained to handle a positive 
identification. There is ample room for interventions and research for community 
pharmacist knowledge and communication related to preventive care. Specifically, 
future research and public health initiatives should focus on community pharmacies as a 
delivery point for more comprehensive preventive care, due to their easy access and 
employment of trained healthcare providers. Additionally, there were a few cases 
where pharmacists found more preventative care omissions than were calculated 
applicable by researchers (example: falls prevention and colorectal screening). This  
could be explained that pharmacists either identified patients’ need beyond the 
stipulations of the USPSTF recommendations. For example, a patient may be at 
increased risk of falls if they are under 65, but on medications that cause dizziness and 
vertigo. Alternatively, it is possible that pharmacists did not understand the USPSTF 




Intervention pharmacists did find some health history more useful than others. Labs 
most useful were related to drug safety and monitoring, such as drug serum levels, A1Cs, 
lipid panels and lung function tests; this is expected as community pharmacists        
would be more likely to encounter ambulatory chronic diseases (as opposed to critical 
care situations with labs such as complete blood counts, and blood gases). Health 
history components most useful to the pharmacists were the active/discontinued 
medication lists as problem lists. We speculate community pharmacists are routinely 
trained to link indications with medications, and may seek out information on 
medication and problem lists specifically as community pharmacists rarely receive 
indications on prescriptions in usual practice. Indeed, pharmacists found more problems 
related to indications than any other medication-related problem. In regards to notes, 
order notes were helpful more often to intervention pharmacists than any other type of 
visit documentation, including office visits and specialist visits. This could be because 
community pharmacists are accustomed to taking orders from physicians, as part of 
their normal filling responsibilities. Interestingly, pharmacists perceived a lack of 
helpfulness of renal labs. This could be due to the fact that patients might have needed 
renal function 
Pharmacists were more likely to report the health history they reviewed was clear and 
helpful if they received it from the PCP rather than from the patient alone. During the 
design of our study, we predicted the possibility that intervention pharmacists could feel 




routinely request medical records in order to participate. However, we detected the 
opposite, as intervention pharmacists were nearly twice more likely than usual care 
pharmacists to report they were comfortable using the health history attained to make 
patient specific recommendations. Utilization of real, unedited health information could 
particularly help community pharmacists especially when the patient is a poor historian, 
has no regular caregiver, and/or has communication/cognitive difficulties. This is further 
supported by the fact that usual care pharmacists (i.e., pharmacists who practice under 
normal conditions and received health history solely from patients) were less likely to 
believe they identified all of the patients’ MRPs. Inferentially, community pharmacists 
under normal conditions cannot always be confident that they are aware of all of the 
patients’ medications, conditions and needs. Van Lint, Sorge and Sorensen identified 
similar results, as pharmacists were more likely to report confidence in the validity of  
the MRP identified once they had reviewed the patient’s medical records. 
Intervention pharmacists were more than twice as likely than usual care pharmacists to 
confidently identify all of the patient’s MRP’s, but were no more likely than usual care 
pharmacists to confidently resolve the MRP’s. There are several reasons that may 
explain this finding- First, we did not ask pharmacists to resolve problems in this study, 
but merely to identify them. Alternatively, this finding could be attributed to confidence 
or workflow issues related to the nature of community pharmacy. Namely, resolving 
problems identified within community pharmacies is limited as there is lack of 




healthcare providers, but within the profession itself. Future research should focus on 
why community pharmacists may identify certain healthcare related problems, but not 
necessarily act to resolve them. 
This study had several limitations; mainly due to the small sample size, few if any 
remarks can be made to the clinical relevance to community pharmacy practice. The 
suggestions related to the results themselves may be promising, as some significant 
suggestions were found, however there may be a low external validity to this study, as 
pharmacists were allowed to choose patients themselves. This is not normal practice, as 
usually patients are referred to community pharmacists via their Medicare Part D, or 
other insurance provider. 
Interest in participation of Rx-SafeNet pharmacists in this study was low, and only a 
handful of pharmacists expressed initial interest in training, with even fewer completing 
training. Pharmacists were compensated for their time, in the form of $150 for training 
and $75 per CMR, which is comparable to other common MTM payers’ compensation, 
however we speculate that pharmacists may not have been incentivized to participate 
as the payment went to the pharmacy itself, and not the pharmacist. This payment 
method was utilized as Purdue University mandates individuals be paid only with the 
use of consulting agreements. We speculate if pharmacists had been compensated 
directly, then there may have been more incentive for study participation. Future 
research in community pharmacy PBRNs may find more success in study participation 




reliance on technicians and other pharmacy staff for some study functions, such as the 
consent process. Regardless of compensation, pharmacists acting as study personnel in 
PBRN research may limit participation and feasibility; as such PBRN studies will be more 
successful if pharmacists act as the provider and not as study personnel. 
Another limitation due to the lackluster enrollment of pharmacists and high attrition, 
was that we could not stratify and match pharmacists based on their experience and 
natural variation in ability to appraise medical history. To account for this variation in 
clinical skills to the best of our ability, we gathered some demographics on the 
pharmacists by asking their past post-graduate training experience and former 
experience with delivering CMRs. Experience between the two pharmacists groups was 
similar in the average number of years practicing (5.0±2.6 vs. 5.5±0.7), but differed in 
relation to CMRs reportedly provided in the last year. While both groups included 
members whom reported no experience ever delivering CMRs, usual care pharmacists 
had more experience than intervention pharmacists, with an average of 6.7 CMRs/year 
vs. 2.5 CMR/s year. One suggestion to reduce this variation was to have a researcher 
obtain the medical records, and reduce the pertinent patient information to a 
standardized form as previous studies have done, with positive results with regards to 
outcomes. However, we decided against an edited medical record form, as the purpose 
of this study was to have pharmacists directly review the medical information 
themselves, as this is an unusual current circumstance, but a plausible possibility as 




review real, unedited medical records as we wanted to measure pharmacists’ opinions 
related to the medical record’s usefulness and usability. 
Because usual care pharmacists had moderately more experience delivering CMRs, we 
would expect the opposite of this study’s findings, however there was such a small 
sample size no definitive conclusions can or should be made. 
Another limitation of this study is that the outcomes were not clinical in nature. Study 
pharmacists only reported the number of identified health related problems, and not 
the patient’s outcome of any action taken (if any action was taken). Any steps taken to 
resolve identified health related problems were up to the sole discretion of the study 
pharmacist and their clinical judgment; additionally interventions made were not 
recorded for this study. Due to this, we are unsure if pharmacists’ confidence in 
resolution of MRP’s was low because steps to intervene were never taken, or because 
the steps taken were perceived inefficient. 
Another limitation results as the quality of records received by intervention pharmacists 
was not recorded. No clinical verification was made in how far each medical record went 
back in the patient’s history, nor the records’ characteristics; we merely recorded each 
type of record received. If we had characterized the quality of the records received, we 
may have been able to study pharmacists’ clinical rationalization more closely, and 
explain findings related to pharmacists’ comfort and confidence. To characterize the 
value pharmacists’ place in medical records more transparently and to mirror transitions 




patients who had a recent hospitalization for conditions targeted under CMS’s Hospital 
Readmission Reduction Program- namely, CHF, COPD, Pneumonia and Hip/Knee 
arthroplasty. However, this was dropped from the final protocol as the patient 
recruitment pool would have been diminished. Future research should focus more 
specifically on pharmacists’ value and rationalization of medical records in clinical 
decision making, and identifying best practices so that they may be taught to future 
pharmacists. 
Lastly, this study was limited due to demographic differences between patient groups. 
Most patients seen in both study groups were females, which is not unexpected, as 
females utilize healthcare more often than males(Bertakis, Azari et al. 2000). However, 
differences emerged in that intervention patients had significantly more conditions and 
medications than usual care patients. It is possible intervention pharmacists were more 
aware of existent conditions and medications due to seeing them on the patient’s 
medical record, and thus had a more complete list of medications and conditions.  Usual 
care pharmacists would only know the conditions and medications reported to them by 
the patient, and since this study did not verify any information the pharmacists  
received, there is no way to assure that these differences identified between groups are 
valid. Future research should focus on the quality of transitions of care processes- 
namely that information being transmitted and appraised is accurate and concise. There 
is a wealth of opportunity for research, as the profession needs to understand how it 
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One-time screening for abdominal aortic aneurysm by 
ultrasonography in men ages 65 to 75 years who have ever 
smoked. 
Alcohol misuse Clinicians screen adults age 18 years or older for alcohol misuse 
and provide persons engaged in risky or hazardous drinking with 
brief behavioral counseling interventions to reduce alcohol 
misuse. 
Aspirin Use aspirin for men ages 45 to 79 years when the benefit due to 
a reduction in myocardial infarctions outweighs the potential 
harm due to an increase in gastrointestinal hemorrhage. 
Aspirin Use aspirin for women ages 55 to 79 years when the benefit of 
reduction in ischemic strokes outweighs the potential harm of 
an increase in gastrointestinal hemorrhage. 
Blood pressure Screen for high blood pressure in adults age 18 years and older. 
BRCA screening, 
counseling about 
Women whose family history is associated with an increased 
risk for deleterious mutations inBRCA1 or BRCA2 genes be 




Clinicians engage in shared, informed decision making with 
women who are at increased risk for breast cancer about 
medications to reduce their risk. For women who are at 
increased risk for breast cancer and at low risk for adverse 
medication effects, clinicians should offer to prescribe risk- 
reducing medications, such as tamoxifen or raloxifene. 
Breast cancer 
screening 
Screen mammography for women, with or without clinical 










cervical cancer in women ages 21 to 65 years with cytology 
(Pap smear) every 3 years or, for women ages 30 to 65 years 
who want to lengthen the screening interval, screening with a 
combination of cytology and human papillomavirus (HPV) 




Screen for chlamydial infection in all sexually active 
nonpregnant young women age 24 years and younger and for 
older nonpregnant women who are at increased risk. 
Cholesterol 
abnormalities 
Screen men age 35 years and older for lipid disorders. 
Cholesterol 
abnormalities 
Screen men ages 20 to 35 years for lipid disorders if they are at 
increased risk for coronary heart disease. 
Cholesterol 
abnormalities 
Screen women age 45 years and older for lipid disorders if they 
are at increased risk for coronary heart disease. 
Cholesterol 
abnormalities 
Screen women ages 20 to 45 years for lipid disorders if they are 
at increased risk for coronary heart disease. 
Colorectal cancer Screen for colorectal cancer using fecal occult blood testing, 
sigmoidoscopy, or colonoscopy in adults beginning at age 50 
years and continuing until age 75 years. 
Depression Screen adults for depression when staff-assisted depression  
care supports are in place to assure accurate diagnosis, effective 
treatment, and follow-up. 
Diabetes Screen for type 2 diabetes in asymptomatic adults with 
sustained blood pressure (either treated or untreated) greater 
than 135/80 mm Hg. 
Falls prevention Exercise or physical therapy to prevent falls in community- 
dwelling adults age 65 years and older who are at increased risk 
for falls. 
Falls prevention in 
older adults: vitamin 
D 
Vitamin D supplementation to prevent falls in community- 
dwelling adults age 65 years and older who are at increased risk 
for falls. 
Folic acid All women planning or capable of pregnancy take a daily 
supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic 
acid. 
Gonorrhea screening: Screen all sexually active women, including those who are 






for infection (that is, if they are young or have other individual 
or population risk factors). 
Healthy diet 
counseling 
Intensive behavioral dietary counseling for adult patients with 
hyperlipidemia and other known risk factors for cardiovascular 
and diet-related chronic disease. Intensive counseling can be 
delivered by primary care clinicians or by referral to other 
specialists, such as nutritionists or dietitians. 
Hepatitis C virus 
infection screening 
Screen for hepatitis C virus (HCV) infection in persons at high 
risk for infection. The USPSTF also recommends offering one- 
time screening for HCV infection to adults born between 1945 
and 1965. 
HIV screening: Screen for HIV infection in adolescents and adults ages 15 to 65 
years. Younger adolescents and older adults who are at 
increased risk should also be screened. 
Intimate partner 
violence screening 
Screen women of childbearing age for intimate partner 
violence, such as domestic violence, and provide or refer 
women who screen positive to intervention services. This 
recommendation applies to women who do not have signs or 
symptoms of abuse. 
Obesity screening and 
counseling 
Screen all adults for obesity. Clinicians should offer or refer 
patients with a body mass index of 30 kg/m2 or higher to 
intensive, multicomponent behavioral interventions. 
Osteoporosis 
screening: women 
Screen for osteoporosis in women age 65 years and older and in 
younger women whose fracture risk is equal to or greater than 




Recommends high-intensity behavioral counseling to prevent 
sexually transmitted infections (STIs) in all sexually active 
adolescents and for adults at increased risk for STIs. 
Skin cancer behavioral 
counseling 
The USPSTF recommends counseling children, adolescents, and 
young adults ages 10 to 24 years who have fair skin about 
minimizing their exposure to ultraviolet radiation to reduce risk 




Ask all adults about tobacco use and provide tobacco cessation 
interventions for those who use tobacco products. 
Syphilis screening Screen persons at increased risk for syphilis infection. 
 
